ElevateBio Raises $525m To Expand Cell And Gene Therapy Expertise

With $845m raised to date, ElevateBio will keep building its cell and gene therapy manufacturing capabilities and continue creating new companies and partnerships, but with a global focus.

businessman standing in front of a blackboard — ElevateBio's third VC round is three times the size of its series B financing • Source: Shutterstock

ElevateBio, LLC was conceived in 2018 as a central hub for both cell and gene therapy R&D and manufacturing that could meet the needs of many regenerative medicine start-ups all the way through commercialization, including ventures founded by the company. With $525m in series C venture capital round announced on 15 March, ElevateBio plans to expand its model to new locations that could support additional companies.

The company has raised $845m to date, including a $150m series A round in 2019 and a $170m series B...